Fosgonimeton is an investigational new drug that is being evaluated to treat neurodegenerative diseases such as Alzheimer's and Parkinson's disease.[1] It is a pro-drug of the active metabolite dihexa. Dihexa in turn binds to the hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met.[2]
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C27H45N4O8P |
Molar mass | 584.651 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ "Fosgonimeton - Athira Pharma". AdisInsight. Springer Nature Switzerland AG.
- ^ Reda SM, Setti SE, Berthiaume AA, Wu W, Taylor RW, Johnston JL, et al. (April 2024). "Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease". Neurotherapeutics. 21 (4): e00350. doi:10.1016/j.neurot.2024.e00350. PMC 11067346. PMID 38599894.